US buys up almost entire stock of Remdesivir, an antiviral drug shown to aid Covid-19 patients


The United States has bought up virtually all stocks for the next three months of a drug shown to work against Covid-19.

The US Department of Health and Human Services (HSS) said it has secured more than 500,000 treatment courses of Remdesivir for American hospitals.

This represents 100% of the US pharmaceutical firm Gilead’s projected production for July, 90% of production in August, and 90% of production in September.

Remdesivir is an antiviral drug that was developed for use against Ebola, but has shown to help in speeding up recovery in people with Covid-19.